Sol-Gel Technologies Ltd. (SLGL)

Market Cap	21.72M
Revenue (ttm)	11.54M
Net Income (ttm)	-10.58M
Shares Out	2.79M
EPS (ttm)	-3.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,080
Open	7.90
Previous Close	7.72
Day's Range	7.63 - 7.95
52-Week Range	3.34 - 16.50
Beta	1.12
Analysts	Strong Buy
Price Target	50.00 (+549.35%)
Earnings Date	Jun 3, 2025

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hype...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGL
• Website: https://www.sol-gel.com

Financial Performance

In 2024, Sol-Gel Technologies's revenue was $11.54 million, an increase of 642.47% compared to the previous year's $1.55 million. Losses were -$10.58 million, -61.16% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for SLGL stock is "Strong Buy." The 12-month stock price forecast is $50.0, which is an increase of 549.35% from the latest price.

Price Target

$50.0

(549.35% upside)

Analyst Consensus: Strong Buy